Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia

Marwan Cheng Kuang Kwok, Andy C Rawstron, Abraham Varghese, Paul Evans, Sheila O'Connor, Chi Doughty, Darren Newton, Paul Moreton, Peter Hillmen

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Eradication of minimal residual disease (MRD) is an independent predictor of survival outcome in patients with chronic lymphocytic leukaemia (CLL) receiving fludarabine and cyclophosphamide (FC) or fludarabine, cyclophosphamide, and rituximab (FCR) as first-line treatment. However, the independent prognostic relevance of MRD status in other therapeutic settings is not clear. The goal of this study was to investigate the independent importance of achieving MRD negativity in CLL on progression-free survival (PFS) and overall survival (OS) with different treatments in frontline and relapsed or refractory settings compared with known prognostic markers.
Original languageEnglish
Title of host publicationLancet
PagesS66
Volume383
DOIs
Publication statusPublished - Feb 2014

Publication series

NameThe Lancet
PublisherElsevier
ISSN (Print)0140-6736

Fingerprint

Dive into the research topics of 'Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia'. Together they form a unique fingerprint.

Cite this